Medical

Danish startup Cessatech, a spin out from Rigshospitalet, announced that it has gotten the go-ahead for a pivotal trial of its CT001 analgesic nasal spray. Cessatech is developing CT001, a fixed dose combination of sufentanil… Read more . . .

Orexo announced the initiation of a Phase 1 trial of its OX640 intranasal dry powder adrenaline, which the company is developing for emergency treatment of anaphylaxis. The OX640-001 study will compare several formulations of OX640… Read more . . .

Receptor Life Sciences said that a Phase 1b/2a trial of its RLS103 cannabidiol DPI in social anxiety disorder patients with acute anxiety has gotten underway. The trial is expected to enroll approximately 30 patients who… Read more . . .

FluGen said that the first subject has been dosed in a Phase 1b study of its M2SR intranasal live single replication flu vaccine and an intramuscular high dose inactivated vaccine (IIV) in adults aged 65 to… Read more . . .

Oragenics has published data from studies of its NT-CoV-2-1 proteosome adjuvanted intranasal vaccine candidate against SARS-CoV-2 in mice and hamsters that support further development of the vaccine, the company said. The data were published June… Read more . . .

Optinose has announced that the Phase 3 ReOpen2 trial of Xhance fluticasone propionate nasal spray (OPN-375) in patients with chronic sinusitis without nasal polyps demonstrated significant improvement compared to placebo in both patient reported symptoms at… Read more . . .

Tiziana Life Sciences has announced that a second multiple sclerosis patient who received the company’s intranasal foralumab for three months as part of an expanded access program at Brigham and Women’s Hospital (BWH) has showed… Read more . . .

Following an advice meeting with the Paul Erhlich Institute, Israeli biopharm company BiondVax Pharmaceuticals announced plans for development of its lead candidate, an inhaled COVID-19 nanosized antibody (NanoAb) therapy. The company said that it hopes… Read more . . .

SoftOx Solutions has announced that a Phase 1 study of its SoftOx inhalation solution (SIS) demonstrated that nebulized SIS was well tolerated with no serious adverse effects observed and no adverse effects related to pulmonary… Read more . . .